| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1 data readout example | ELI-002 7P (investigational AMP cancer vaccine) borderline and resectable pancreatic ductal adenocarcinoma (PDAC) | Phase 1 | — | Vaccines | Oncology | ||
phase 1 data readout example | ELI-002 7P (investigational AMP cancer vaccine) borderline and resectable pancreatic ductal adenocarcinoma (PDAC) | Phase 1 | — | Vaccines | Oncology | ||
phase 1 data readout example | ELI-002 7P (investigational AMP cancer vaccine) borderline and resectable pancreatic ductal adenocarcinoma (PDAC) | Phase 1 | — | Vaccines | Oncology |
Recent Updates
Recently added Catalysts
Elicio Therapeutics, Inc.$14.85
+0.91 (+6.53%)
F 16Pipeline Score Richly Valued Biotech · Commercial
Market Cap
189.91 M
EPS
-2.34
P/E Ratio
-
Value Trade
1.82 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
6.76 M
Operating CF
-11.64 M
Total Assets
22.69 M
Total Liabilities
24.13 M
Equity
-1.44 M
D/E Ratio
12,345
-6.92 %
Week
-18.31 %
1 Month
14.37 %
3 Month
23.6 %
6 Month
-93.83 %
5 Year
-94.35 %
All Time
Cash Data
Cash Position
14.95 M
Monthly Burn
3.88 M
Runway
2.9 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
125.44 K
52 Week Range
5.80 - 14.93
% held by Insiders
32.27 %
% held by Institutions
13.98 %
Enterprise Value
189.30 M
Total Shares
17.48 M
Short %
17.22 %
Float Shares
11.01 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F16
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 14%
Micro Cap (rank 779 of 905)
Percentile RankElicio Therapeutics, Inc. has significant pipeline risk (16/100), with $20M risk-adjusted pipeline value, led by ELI-002 7P in Pancreatic Ductal Adenocarcinoma (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELI-002 7P Small molecule | Pancreatic Ductal Adenocarcinoma | Phase 1 | NCT05726864 | 5% | $12M | ACTIVE NOT_RECRUITING | 158 | VERY_FAST | C (52) | Nov 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ELI-002 7P | pancreatic ductal adenocarcinoma | Phase 2 | 2025-08-06 | |||
ELI-002 7P | pancreatic ductal adenocarcinoma | Phase 2 | 2025-08-06 | |||
ELI-002 7P | pancreatic ductal adenocarcinoma | Phase 2 | 2025-08-06 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ELTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ELTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ELTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ELTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-11-20 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Elicio Therapeutics, Inc. (ELTX) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How ELTX ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Pancreatic Cancer | #35 of 72 | ELI-002 7P | RVMD RCUS AZN | $3.7B | 0.84 | ||
| Colorectal Cancer | #42 of 82 | ELI-002 7P | ABBV BMY MRK | $7.68B | 0.84 |